Clinical trials: Nephrotic Syndrome, Minimal Change
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Nephrotic Syndrome
IL-2 for Multi Drug Resistant Nephrotic Syndrome
The aim of the study is to design an open-label phase 1-2 trial to assess safety and clinical and immunologic effects of repeated administration of recombinant low dose IL2 (Proleukin) in 5 patients with idiopathic nephrotic…
- Trial name
- NCT02455908
- Testing
- Proleukin®
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Istituto Giannina Gaslini
Minimal Change Disease
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in…
- Trial name
- NCT06405100
- Testing
- Supportive care+Prednisone, Supportive care+Tacrolimus+Ripertamab, Supportive care+Ripertamab
- Volunteers
- 81 people
- Sponsor
- Air Force Military Medical University, China
Nephrotic Syndrome, Minimal Change
Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome
The initial steroids dose for Nephrotic Syndrome is 60mg/1m2 for 6-4 weeks and the duration of the first steroid course is between 8 weeks to 6 months.
- Trial name
- AJSNS (NCT02649413)
- Testing
- Prednisone
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Rabin Medical Center
Nephrotic Syndrome
Prednisolone Trial in Children Younger Than 4 Years
This study is a multicentric, randomized, parallel group, open label controlled trial of children age 1 year up to 4 years with new onset, idiopathic nephrotic syndrome.
- Trial name
- NCT03141970
- Testing
- Prednisolone
- Where
- 5 sites in United States, India
- Volunteers
- 170 people
- Sponsor
- All India Institute of Medical Sciences
NEPHROSIS, LIPOID
Latent Viral Infection of Lymphoid Cells in Idiopathic Nephrotic Syndrome
The primary purpose of the study is to evaluate the association of a latent infection of lymphoid cells during the first manifestation of steroid sensitive nephrite syndrome.
- Trial name
- Nephrovir (NCT00577525)
- Where
- France
- Volunteers
- 401 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Childhood Idiopathic Nephrotic Syndrome
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25…
- Trial name
- INShore (NCT05627557)
- Testing
- Obinutuzumab, MMF, Prednisone
- Where
- 35 sites in United States, Belgium and 7 more
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Nephrotic Syndrome (INS)
Comparison of Efficacy and Safety of Albumin Versus Fresh Frozen Plasma in Managing Diuretic Resistant Edema in Children With Idiopathic Nephrotic Syndrome.
Edema is a major component of nephrotic syndrome (NS), defined by Kidney Disease Improving Global Outcomes (KDIGO) guidelines is, urine protein/creatinine ratio ≥ 2 mg/mg, and hypoalbuminemia ≤ 2.5 g/dl).
- Trial name
- ALB-FFP (NCT07685093)
- Testing
- Human Albumin 20%, Fresh Frozen Plasma
- Volunteers
- 56 people
- Sponsor
- Qamar Shafiq
Primary Membranous Nephropathy, Minimal Change Disease
A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease
This study will assess whether sibeprenlimab can help improve kidney disease in adults with primary membranous nephropathy (pMN) by reducing harmful antibodies linked to the disease.
- Conditions
- Primary Membranous Nephropathy, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- NCT07861113
- Testing
- Sibeprenlimab
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Focal Segmental Glomerulosclerosis
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
Idiopathic Focal Segmental Glumero Sclerosis (FSGS) is not very common but important manifestation of kidney disease. FSGS has poor prognosis among the patterns of Idiopathic Nephrotic Syndrome (INS).
- Trial name
- NCT02382874
- Testing
- Intravenous injection
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Royan Institute
Nephrotic Syndrome
Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
This retrospective study is aimed at evaluating the levels of circulating anti-nephrin autoantibodies in patients with INS, including those with MCD/FSGS and in patients who have experienced relapse of FSGS post-transplant…
- Trial name
- BLINDER (NCT06334692)
- Testing
- In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa).
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Minimal Change Nephrotic Syndrome (MCNS)
RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome
Minimal change nephrotic syndrome (MCNS) is an acquired glomerular disease characterized by massive proteinuria occurring in the absence of glomerular inflammatory lesions or immunoglobulin deposits.
- Trial name
- RIFIREINS (NCT03970577)
- Testing
- Rituximab, Prednisone
- Where
- France
- Volunteers
- 148 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Minimal Change Disease, Nephrotic Syndrome
Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
Traditionally MCN is treated with a high dose of prednisolone, which induces remission in 60-90% of patients. Prednisolone treatment contains numerous side effects and the current dose is empiric.
- Trial name
- ADAPTinMCN (NCT03210688)
- Testing
- Prednisolone, Alfacalcidol
- Where
- 2 sites in Denmark
- Volunteers
- 71 people
- Sponsor
- University of Aarhus
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and…
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Trial name
- RESOLVE (NCT05650619)
- Testing
- Biospecimen collection, Data collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Idiopathic Nephrotic Syndrome (INS)
Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
Renal biopsy (RB) is the reference diagnostic procedure for Idiopathic Nephrotic Syndrome (INS). It is an invasive procedure, particularly risky during the acute phase of nephrotic syndrome when anticoagulation therapy is…
- Trial name
- DNI-SNI (NCT06820866)
- Where
- France
- Volunteers
- 265 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nephrotic Syndrome，Idiopathic
Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study
This study is to assess the efficacy and safety of 8-weeks full-dose induction protocol (prednisone 1mg/kg, maximum 60mg/day) and protracted tapering protocol in the treatment of adult idiopathic nephrotic syndrome.
- Trial name
- NCT02298335
- Testing
- prednisone
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Nanjing University School of Medicine
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis
NEPTUNE Match Study
NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.
- Conditions
- Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome
- Trial name
- NEPTUNE Match (NCT04571658)
- Testing
- Communication
- Where
- 16 sites in United States
- Volunteers
- 375 people
- Sponsor
- University of Michigan
Nephrotic Syndrome
Pharmacokinetics of Cyclosporin in Nephrotic Syndrome
The purpose of this study is to evaluate whether there are differences in the pharmacokinetics of cyclosporine in remission nephrotic syndrome compared to relapsed disease in children.
- Trial name
- NCT01616446
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- University of Sao Paulo
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
Various studies have been conducted to identify effective treatment strategies for primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) so far.
- Trial name
- NCT04369183
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Istanbul University